Telomir Pharmaceuticals Files 8-K Report
Ticker: TELO · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, disclosure, regulatory-filing
TL;DR
Telomir Pharma (TLO) filed an 8-K on Oct 6th for 'Other Events'.
AI Summary
On October 6, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporated in Florida and its principal executive offices are located in Miami, Florida.
Why It Matters
This filing signals a material event or change for Telomir Pharmaceuticals, Inc., requiring disclosure to investors and the public.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form (8-K) and does not, on its own, indicate significant financial or operational risk.
Key Numbers
- 001-41952 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-2606031 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
FAQ
What specific 'Other Events' are being reported by Telomir Pharmaceuticals, Inc. in this 8-K filing?
The provided text does not detail the specific 'Other Events'; it only states that this is the item being reported.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 6, 2025.
What is Telomir Pharmaceuticals, Inc.'s principal executive office address?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 15.9 · Accepted 2025-10-06 16:01:44
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-25-017072.txt ( ) — 204KB
- telo-20251006.xsd (EX-101.SCH) — 3KB
- telo-20251006_lab.xml (EX-101.LAB) — 33KB
- telo-20251006_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: October 6, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer